Answers are grounded in this paper and cite their sources.
Background Chimeric antigen receptor T-cell (CAR-T) therapy is a major advancement in targeted oncology using living biodrugs. Though CAR-T is clinically successful, treatment-related toxicities are still a limitation. Aim This meta-analysis goes beyond routine response rate assessment to quantitatively evaluate the incidence, variability, and determinants of CAR-T associated toxicities, including cytokine release syndrome (CRS), Immune effector cell-associated neurotoxicity syndrome (ICANS), and Treatment-related mortality (TRM), across clinical trials. Methods We conducted a comprehensive literature search in ClinicalTrials.gov and PubMed through August 28, 2026, using predefined Medical Subject Headings (MeSH) terms and keywords related to CAR-T, TRUCKs, toxicity, and cancer. Eligible studies included Phase I–IV clinical trials reporting toxicities. The meta-analysis included 21 studies comprising 1,692 patients and 1,084 CRS events. We used a random-effects model to estimate the logit-transformed (PLOGIT) incidence. We analyzed 21 studies, including 1,692 patients receiving CAR-T therapy. The pooled CRS incidence was 77.6% (95% CI, 64.2–87.0.1; k = 17), with heterogeneity (I 2 = 91.4%, τ 2 = 0.939, p < 0.001). Subgroup analysis showed significant variation in CRS incidence across malignancy types (Q = 197.97, p < 0.001). ICANS occurred in 30.6% of patients (95% CI, 19.2–44.8; k = 21), with high heterogeneity (I 2 = 92.3%). Treatment-related mortality was uncommon, occurring in 4.6% of patients (95% CI, 3.5 – 5.9; k = 19), with heterogeneity (I 2 = 0.0%). Findings show that CRS is highly prevalent, and methodological and clinical factors influence its reported incidence. Conclusion CAR-T therapy is associated with a high incidence of CRS and clinically relevant ICANS, while TRM remains infrequent. Variability in CRS and ICANS rates may reflect differences in disease characteristics, CAR-T products, and toxicity assessment methods, underscoring the need for standardized monitoring and risk-based management. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/ , identifier CRD420261452061.
No takes yet. Share an insight, caveat, or question.
Yusuf et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: